Design, synthesis, and apoptotic antiproliferative action of new benzimidazole/1,2,3-triazole hybrids as EGFR inhibitors.

ABSTRACT:

Introduction

This work outlines the design, synthesis, and biological evaluation of a new series of benzimidazole/1,2,3-triazole hybrids as apoptotic antiproliferative agents that inhibit the EGFR pathway.

Methods

The research assesses the antiproliferative efficacy of compounds 6a-i and 10a-i against various cancer cell lines.

Results and discussion

The research emphasizing hybrids 6i and 10e for their remarkable activity, with GI₅₀ values of 29 nM and 25 nM, respectively. The inhibitory effects of the most potent hybrids 6e, 6i, 10d, 10e, and 10g on EGFR were assessed. Compounds 6i and 10e exhibited greater potency than erlotinib as EGFR inhibitors. Compounds 6i and 10e

SUBMITTER: Ahmed AAY 

PROVIDER: S-EPMC11783063 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature